AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
+7.88%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$3.12B
AUM Growth
+$3.12B
(+86%)
Cap. Flow
+$1.35B
Cap. Flow
% of AUM
43.26%
Top 10 Holdings %
Top 10 Hldgs %
70.07%
Holding
139
New
20
Increased
22
Reduced
19
Closed
25
Top Buys
| 1 |
CAVA Group
CAVA
|
$1.31B |
| 2 |
Lexicon Pharmaceuticals
LXRX
|
$63.6M |
| 3 |
SLRN
ACELYRIN
SLRN
|
$38.1M |
| 4 |
MoonLake Immunotherapeutics
MLTX
|
$20.4M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$18.7M |
Top Sells
| 1 |
WW
WW International
WW
|
$61.1M |
| 2 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$15.8M |
| 3 |
Apellis Pharmaceuticals
APLS
|
$15.1M |
| 4 |
Fate Therapeutics
FATE
|
$14.8M |
| 5 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$13.1M |
Sector Composition
| 1 | Healthcare | 56.49% |
| 2 | Consumer Discretionary | 42.78% |
| 3 | Technology | 0.24% |
| 4 | Financials | 0.2% |
| 5 | Real Estate | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CAVA Group
CAVA
$7.83B
| $1.31B | 40.62% | +32,007,990 | New | +$1.31B |
|
|
2
Lexicon Pharmaceuticals
LXRX
$400M
| $269M | 8.34% | 117,553,284 +27,775,050 | +31% | +$63.6M |
|
|
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $123M | 3.8% | 2,139,995 +326,046 | +18% | +$18.7M |
|
|
4
Apellis Pharmaceuticals
APLS
$3.48B
| $95.7M | 2.96% | 1,050,067 -166,245 | -14% | -$15.1M |
|
|
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $74.3M | 2.3% | 2,055,181 +517,472 | +34% | +$18.7M |
|
|
ONC
6
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $73.5M | 2.28% | 412,496 -88,839 | -18% | -$15.8M |
|
7
Scholar Rock
SRRK
$3.14B
| $68.3M | 2.12% | 9,059,507 +31,557 | +0.3% | +$238K |
|
8
Revolution Medicines
RVMD
$7.1B
| $64.2M | 1.99% | 2,401,617 +330,629 | +16% | +$8.84M |
|
9
Amicus Therapeutics
FOLD
$2.34B
| $57.3M | 1.78% | 4,562,567 +1,036,160 | +29% | +$13M |
|
|
CERE
10
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $52.1M | 1.61% | 1,638,858 -275,608 | -14% | -$8.76M |
|
|
SWTX
11
DELISTED
SpringWorks Therapeutics
SWTX
| $47.6M | 1.48% | 1,816,620 -729 | -0% | -$19.1K |
|
12
Cytokinetics
CYTK
$4.23B
| $46.2M | 1.43% | 1,416,031 +49,008 | +4% | +$1.6M |
|
13
Kymera Therapeutics
KYMR
$2.95B
| $41.5M | 1.29% | 1,805,346 | – | – |
|
14
Krystal Biotech
KRYS
$4.27B
| $41.1M | 1.27% | 349,669 -62,413 | -15% | -$7.33M |
|
|
SLRN
15
DELISTED
ACELYRIN
SLRN
| $38.1M | 1.18% | +1,821,214 | New | +$38.1M |
|
16
Schrodinger
SDGR
$1.44B
| $34.9M | 1.08% | 700,000 | – | – |
|
|
AGEN
17
Agenus
AGEN
$133M
| $25M | 0.78% | 15,631,235 | – | – |
|
18
Denali Therapeutics
DNLI
$2.23B
| $23.7M | 0.73% | 802,899 | – | – |
|
|
SAGE
19
DELISTED
Sage Therapeutics
SAGE
| $23.5M | 0.73% | 500,000 -250,000 | -33% | -$11.8M |
|
|
IGMS
20
DELISTED
IGM Biosciences
IGMS
| $23.3M | 0.72% | 2,522,244 +12,272 | +0.5% | +$113K |
|
|
KLRS
21
Kalaris Therapeutics, Inc. Common Stock
KLRS
$76.3M
| $22.4M | 0.7% | 6,597,167 +1,020,000 | +18% | +$3.47M |
|
22
Kura Oncology
KURA
$686M
| $21.4M | 0.66% | 2,018,056 +300,000 | +17% | +$3.17M |
|
|
23
MoonLake Immunotherapeutics
MLTX
$3.54B
| $20.4M | 0.63% | +400,000 | New | +$20.4M |
|
24
Sea Limited
SE
$110B
| $20.3M | 0.63% | 350,000 +47,500 | +16% | +$2.76M |
|
25
Seer Inc
SEER
$115M
| $20.3M | 0.63% | 4,750,000 | – | – |
|